The CMS on Wednesday released a decision memo agreeing to cover one beta-amyloid PET scan per patient under certain conditions, including that the clinical study where the PET scan will be used is approved by the CMS and that the radiopharmaceuticals used are cleared by the FDA. Advocates were hoping for a broader coverage decision, but the CMS argued in its memo that there is not enough evidence that beta-amyloid PET imaging leads to better health outcomes for patients with neurodegenerative disease or dementia. The agency, however, said that PET imaging has the potential to distinguish Alzheimer's disease from "narrowly defined and clinically difficult differential diagnoses."

Related Summaries